SITEMAP 창 닫기

CEO & President Wonbum Lee
Sales Revenue(2025) 254,712 Million KRW
Stock Exchange Index KOSPI
Head Office Seoul, Korea
KGMP Plant Anseong, Korea / Hyangnam, Korea
R&D center Yongin, Korea / Seoul, Korea
Main Therapeutic Areas Central Nervous System (83%)
Cardiovascular (4%)
Gastrointestinal (2%)
Main Products Quetiapine/Agomelatine/Escitalopram/Alprazolam